Title Category Credit Event datesort ascending Cost
Oncology Clinical Briefing: Expert Insights for Managing Bladder Cancer in the Time of COVID-19
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00 As the novel coronavirus, SARS-CoV-2, spreads across the globe, and as confirmed cases of COVID-19 infection continue to climb, we are being ushered into circumstances which are unprecedented in modern times. It is thus absolutely vital that oncology clinicians, who manage a patient population at very high risk for severe manifestations of COVID-19, be informed regarding adaptive ways to keep their patients safe. To help meet that need, this online educational activity will review the ever-changing epidemiology of COVID-19 and identify primary infection risk concerns for cancer patients.
Oncology Clinical Briefing: Expert Insights for Managing Breast Cancer in the Time of COVID-19
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00 As the novel coronavirus, SARS-CoV-2, spreads across the globe, and as confirmed cases of COVID-19 infection continue to climb, we are being ushered into circumstances which are unprecedented in modern times. It is thus absolutely vital that oncology clinicians, who manage a patient population at very high risk for severe manifestations of COVID-19, be informed regarding adaptive ways to keep their patients safe. To help meet that need, this online educational activity will review the ever-changing epidemiology of COVID-19 and identify primary infection risk concerns for cancer patients.
Best Practices for Using Long-acting Injectable Antipsychotics during COVID-19
  • Psychiatry
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
$0.00 In recent years, the landscape for the treatment of severe mental illness such as schizophrenia has evolved with increasing use of long-acting injectable antipsychotics (LAIs) as new data tout significant benefits of these agents over oral treatment. Early randomized, controlled trials did not show superiority of LAIs over oral antipsychotics. However, in recent years, overwhelming evidence suggests that LAIs may improve adherence, reduce relapse and hospitalizations, lessen the risk of treatment failure, and decrease mortality.
Navigating The Treatment of Schizophrenia Using LAIs In The Time of COVID-19
  • Psychiatry
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00 In recent years, the landscape for the treatment of severe mental illness such as schizophrenia has evolved with increasing use of long-acting injectable antipsychotics (LAIs) as new data tout significant benefits of these agents over oral treatment. Early randomized, controlled trials did not show superiority of LAIs over oral antipsychotics. However, in recent years, overwhelming evidence suggests that LAIs may improve adherence, reduce relapse and hospitalizations, lessen the risk of treatment failure, and decrease mortality.
Optimizing the Role of the Pharmacist in LAI Administration During COVID-19
  • Psychiatry
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
$0.00 In recent years, the landscape for the treatment of severe mental illness such as schizophrenia has evolved with increasing use of long-acting injectable antipsychotics (LAIs) as new data tout significant benefits of these agents over oral treatment. Early randomized, controlled trials did not show superiority of LAIs over oral antipsychotics. However, in recent years, overwhelming evidence suggests that LAIs may improve adherence, reduce relapse and hospitalizations, lessen the risk of treatment failure, and decrease mortality.
Stepping Beyond the Status Quo in Heart Failure: The Revolutionary Role of SGLT2 Inhibition
  • Cardiology
$0.00 Click here to complete this activity

Pages